[Abstract Only] Randomized Trial: GLP-1 Receptor Agonist Superior to SGLT2 Inhibitor for Glucose Control and Weight Loss in Patients with Type 2 Diabetes Uncontrolled on Metformin Therapy

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial – The Lancet Endocrinology & Metabolism (link to abstract – $ for full-text)

Commentary: Add-On Diabetes Treatment: Semaglutide Improves HbA1c Better Than Canagliflozin – NEJM Journal Watch (free)